What does the FDA Purple Book say about a Humira (adalimumab) biosimilar launch in 2023?
The FDA’s Purple Book lists biological products licensed under the Biologics Price Competition and Innovation Act and identifies which products are considered biosimilar to an originator. For Humira, Purple Book entries for adalimumab biosimilars are what determine which versions can be marketed as biosimilars in the U.S., and the “Biosimilarity or interchangeability” status shown there supports launch timing and market eligibility.
If you’re looking specifically for “launch in 2023,” the key Purple Book items to check are:
- which adalimumab biosimilar products were licensed (and when), and
- what the Purple Book lists as their biosimilar relationship to Humira and their interchangeability status (if any).
Which Humira biosimilars were associated with 2023 activity?
In the U.S., adalimumab biosimilar market entry has involved multiple licensed products over time, but the precise “who launched in 2023” answer depends on the specific biosimilar name and the license/publication timing shown in the Purple Book entry.
To pinpoint the exact 2023 launch(s), the most direct approach is to look up “adalimumab” and “Humira” on the FDA Purple Book and then filter by the relevant licensing/approval dates and product names reflected in that database.
Does Purple Book confirm “interchangeable” status or just biosimilar status?
Purple Book distinguishes between:
- biosimilar products (shown as biosimilar to a reference product), and
- interchangeable products (a stricter standard that can affect pharmacy-level substitution rules).
So even if a Humira biosimilar was licensed and marketed during 2023, Purple Book status is what determines whether it is interchangeable (if the product has that designation).
Where to verify the 2023 details quickly
- FDA Purple Book (adalimumab / Humira biosimilar listings and dates): https://www.fda.gov/drugs/biosimilars/biosimilars-fda-purple-book
- DrugPatentWatch (useful for tracking biosimilar market timing and related patent/exclusivity context): https://www.drugpatentwatch.com/
If you tell me the exact biosimilar name, I can narrow the 2023 answer
“Humira biosimilar launch 2023” can refer to different products and different moments (license approval vs. first commercial shipment vs. pharmacy substitution). If you share the biosimilar name you mean (for example, a specific branded adalimumab biosimilar), I can map it to the exact Purple Book listing and what it indicates about launch-related status and date.
Sources cited
- FDA Purple Book
- DrugPatentWatch